Literature DB >> 21602094

Validity of the FACT-H&N (v 4.0) among Malaysian oral cancer patients.

J G Doss1, W M Thomson, B K Drummond, R J Raja Latifah.   

Abstract

To assess the cross-sectional construct validity of the Malay-translated and cross-culturally adapted FACT-H&N (v 4.0) for discriminative use in a sample of Malaysian oral cancer patients. A cross-sectional study of adults newly diagnosed with oral cancer. HRQOL data were collected using the FACT-H&N (v 4.0), a global question and a supplementary set of eight questions ('MAQ') obtained earlier in pilot work. Of the 76 participants (61.8% female; 23.7% younger than 50), most (96.1%) had oral squamous cell carcinoma; two-thirds were in Stages III or IV. At baseline, patients' mean FACT summary (FACT-G, FACT-H&N, FACT-H&N TOI, and FHNSI) and subscale (pwb, swb, ewb, fwb, and hnsc) scores were towards the higher end of the range. Equal proportions (36.8%) rated their overall HRQOL as 'good' or 'average'; fewer than one-quarter rated it as 'poor', and only two as 'very good'. All six FACT summary and most subscales had moderate-to-good internal consistency. For all summary scales, those with 'very poor/poor' self-rated HRQOL differed significantly from the 'good/very good' group. All FACT summary scales correlated strongly (r>0.75). Summary scales showed convergent validity (r>0.90) but little discriminant validity. The discriminant validity of the FHNSI improved with the addition of the MAQ. The FACT-H&N summary scales and most subscales demonstrated acceptable cross-sectional construct validity, reliability and discriminative ability, and thus appear appropriate for further use among Malaysian oral cancer patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21602094     DOI: 10.1016/j.oraloncology.2011.04.023

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  Can post-treatment oral cancer patients' concerns reflect their cancer characteristics, HRQoL, psychological distress level and satisfaction with consultation?

Authors:  Ainon Natrah Aminnudin; Jennifer Geraldine Doss; Siti Mazlipah Ismail; Ma Bee Chai; Marzuki Zainal Abidin; Cri Saiful Jordan Milano Basri; Nurshaline Pauline Kipli; Lee Chee Wei
Journal:  Ecancermedicalscience       Date:  2020-10-08

2.  Risk factors associated with the mortality rate of oral squamous cell carcinoma patients: A 10-year retrospective study.

Authors:  Paras Ahmad; Rubbia Nawaz; Maria Qurban; Gul Muhammad Shaikh; Roshan Noor Mohamed; Anil Kumar Nagarajappa; Jawaad Ahmed Asif; Mohammad Khursheed Alam
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

3.  Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center.

Authors:  Bing-Qing Xu; Zi-Wei Tu; Ya-Lan Tao; Zhi-Gang Liu; Xiao-Hui Li; Wei Yi; Chang-Bing Jiang; Yun-Fei Xia
Journal:  Chin J Cancer       Date:  2016-04-07

4.  Measurement properties of oral health related patient reported outcome measures in patients with oral cancer: A systematic review using COSMIN checklist.

Authors:  Shailesh M Gondivkar; Amol R Gadbail; Sachin C Sarode; Rima S Gondivkar; Monal Yuwanati; Gargi S Sarode; Shankargouda Patil
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

5.  Acceptance and commitment therapy versus mindfulness-based stress reduction for newly diagnosed head and neck cancer patients: A randomized controlled trial assessing efficacy for positive psychology, depression, anxiety, and quality of life.

Authors:  Zheng Zhang; Mohammad Farris Iman Leong Bin Abdullah; Nurul Izzah Shari; Ping Lu
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

6.  Translation, linguistic validation and reliability of FACT-H&N questionnaire in Oral Cancer patients in Sudan.

Authors:  M El Sheikh; A Suleiman; A Satti; E M O'Sullivan
Journal:  J Patient Rep Outcomes       Date:  2022-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.